THTX stock keeps "Buy" rating at Research Capital
Following the company’s fourth quarter results, Research Capital analyst Andre Uddin has maintained his “Buy” rating on Theratechnologies.
Source: cantechletter.com
Andre Uddin News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Andre Uddin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Andre Uddin Today - Breaking & Trending Today
MDNA is undervalued, Research Capital says
Following the company’s third quarter results, Research Capital analyst Andre Uddin has kept his “Speculative Buy” rating on Medicenna Therapeutics
Source: cantechletter.com
Medexus earns price target raise at Research Capital
Following moves by the company to shore up its balance sheet, Research Capital analyst Andre Uddin is feeling a little more bullish about MDP.
Source: cantechletter.com
Sernova (TSX:SVA) stock is cheap, Research Capital says
Following the release of new data on a core offering, Research Capital analyst Andre Uddin remains upbeat about the prospects of Sernova.
Source: cantechletter.com
SVA stock is undervalued, Research Capital says
A management shuffle at Sernova Corp isn’t dampening analyst Andre Uddin’s enthusiasm for the stock..
Source: cantechletter.com